Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment
| Autor: | J. J. Mould, T. N. Latief, M. Morrison, David Spooner, George Blackledge |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
medicine.medical_specialty Medroxyprogesterone medicine.medical_treatment Mammary gland Antineoplastic Agents Bone Neoplasms Breast Neoplasms Medroxyprogesterone Acetate Gastroenterology chemistry.chemical_compound Internal medicine medicine Medroxyprogesterone acetate Humans Aged Chemotherapy Progestogen business.industry Megestrol Acetate Cancer Megestrol Middle Aged medicine.disease Hormones Surgery medicine.anatomical_structure Oncology chemistry Megestrol acetate Hormonal therapy Drug Evaluation Female business medicine.drug |
| Zdroj: | European journal of cancerclinical oncology. 22(9) |
| ISSN: | 0277-5379 |
| Popis: | Thirty-seven patients with advanced breast cancer were treated with megestrol acetate 160 mg daily. All patients except two had been heavily pre-treated with hormonal therapy; eight patients also received chemotherapy. Complete and partial responses occurred in 25% with a mean duration of 5 months (range 2–24 months ). A further 38% of patients had static disease for 2 months or greater. Seven patients had previously received medroxyprogesterone acetate, and responses were seen even in patients who had failed to respond to this therapy. This was thought to be due to the higher levels of progestogenic activity which can be routinely achieved with megestrol acetate. Toxicity was minimal, and we would therefore consider that megestrol acetate should be the progestogen of choice in advanced breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|